Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid

Clin Nucl Med. 1993 Aug;18(8):657-61. doi: 10.1097/00003072-199308000-00005.

Abstract

The 10-year survival rate for medullary carcinoma of the thyroid (MCT) is 50%; thus, good tumor-seeking radiopharmaceuticals are needed to localize foci of recurrence and metastasis during follow-up. Two patients with metastatic MCT were studied with Tl-201, I-131 MIBG, Tc-99m (V)-DMSA, and Tc-99m MIBI. A SPECT study with the latter agent allowed the visualization and precise localization of a metastatic mediastinal lymph node. More studies need to be done to evaluate the role of Tc-99m MIBI in the detection of recurrence and metastases of MCT.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Medullary / diagnostic imaging*
  • Carcinoma, Medullary / secondary
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Lymphatic Metastasis / diagnostic imaging
  • Male
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Organotechnetium Compounds
  • Succimer
  • Technetium Tc 99m Dimercaptosuccinic Acid
  • Technetium Tc 99m Sestamibi*
  • Thyroid Neoplasms / diagnostic imaging*
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Organotechnetium Compounds
  • Technetium Tc 99m Dimercaptosuccinic Acid
  • Technetium Tc 99m Sestamibi
  • Succimer